Determination of Blood Loss After CS

Tranexamic Acid Plus Oxytocin Versus Oxtocin Only in Reducing Blood Loss After Cesarean Section

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04549012

Enrollment

130

Registered

2020-09-16

Start date

2020-09-30

Completion date

2021-10-31

Last updated

2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of Drug

Brief summary

Comparing betweeen tranexamic acid plus oxytocin and oxytocin alone in their efficacy in reducing blood loss following CS

Detailed description

tranexamic acid plus oxytocin versus oxytocin only in reducing blood loss following CS

Interventions

DRUGTranexamic acid

comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS

DRUGOxytocin

Oxytocin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Masking description

women will be given serial number ,randomization will be done through a computer generated system

Intervention model description

Group (A) will receive oxytocin only Group (B)will receive oxytocin plus tranexamic acid

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age : 20-40 year * 2- Gestational age is between 37-41weeks 3- Delivery by uncomplicated elective CS

Exclusion criteria

* 1- Risk factors for uterine atony such as polyhydramnios or fetal macrosomia. 2- Grandmultiparity 3- Past history of postpartum hemorrhage either atonic or traumatic 4- Previous history of retained placenta 5- Pre-eclampsia or gestational hypertension/ Maternal DM 6- Abnormal placentation 7- Contraindications to the use of tranexamic acid 8- Hypersensitivity to tranexamic acid. 9- Women receiving anticoagulant therapy. 10- having underlying disease (heart, liver, kidney, pulmonary, etc.),

Design outcomes

Primary

Measure	Time frame	Description
amount of blood loss	baseline	comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS

Secondary

Measure	Time frame	Description
maternal and neonatal complication	baseline	blood transfusion ,surgical injuries ,

Contacts

Primary Contactnoha abu shata

mhmwdnhy44@gmail.com01000287839

Backup Contacttamer Borg

tamerborg1975@gmail.com01001457437

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026